{
    "organizations": [],
    "uuid": "c07b3d872ec0165609f509af48da22b0c479e0d2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oasmia-pharma-says-all-patients-ha/brief-oasmia-pharma-says-all-patients-have-been-treated-in-two-ongoing-studies-with-docecal-idUSFWN1Q901N",
    "ord_in_thread": 0,
    "title": "BRIEF-Oasmia Pharma says all patients have been treated in two ongoing studies with Docecal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 19 (Reuters) - Oasmia Pharmaceutical AB:\n* REG-OASMIA PHARMACEUTICAL’S DOCECAL PROGRAM ACHIEVES SIGNIFICANT DEVELOPMENT MILESTONE\n* SAYS ‍ANNOUNCES THAT ALL PATIENTS HAVE BEEN TREATED IN TWO ONGOING STUDIES WITH DOCECAL IN METASTATIC BREAST CANCER\n* SAYS THE WORK TO COMPILE THE RESULTS IS ONGOING * SAYS POSITIVE RESULTS FROM THE STUDY PROGRAM WILL BE SUFFICIENT TO APPLY FOR SALES- AND MARKETING APPROVAL IN RUSSIA, WHICH IS ONE OF THE WORLD’S FASTEST GROWING ONCOLOGY MARKETS\n* OASMIA PLANS TO SUBMIT FOR APPROVAL DURING THE SECOND HALF OF 2018\n* INTENDS TO INITIATE DISCUSSIONS REGARDING POSSIBLE REGISTRATION OF DOCECAL BASED ON THE CURRENT PROGRAM WITH EMA FOR THE EU AND WITH THE FDA FOR THE USA​ Source text for Eikon: Further company coverage: (Stockholm Newsroom)\n ",
    "published": "2018-02-19T15:36:00.000+02:00",
    "crawled": "2018-02-20T14:28:58.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "oasmia",
        "pharmaceutical",
        "ab",
        "pharmaceutical",
        "docecal",
        "program",
        "achieves",
        "significant",
        "development",
        "milestone",
        "say",
        "patient",
        "treated",
        "two",
        "ongoing",
        "study",
        "docecal",
        "metastatic",
        "breast",
        "cancer",
        "say",
        "work",
        "compile",
        "result",
        "ongoing",
        "say",
        "positive",
        "result",
        "study",
        "program",
        "sufficient",
        "apply",
        "marketing",
        "approval",
        "russia",
        "one",
        "world",
        "fastest",
        "growing",
        "oncology",
        "market",
        "oasmia",
        "plan",
        "submit",
        "approval",
        "second",
        "half",
        "intends",
        "initiate",
        "discussion",
        "regarding",
        "possible",
        "registration",
        "docecal",
        "based",
        "current",
        "program",
        "ema",
        "eu",
        "fda",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "stockholm",
        "newsroom"
    ]
}